Concerta XL 36 mg prolonged-release tablets
- Name:
Concerta XL 36 mg prolonged-release tablets
- Company:
Janssen Sciences Ireland
- Active Ingredients:
- Legal Category:
Product subject to medical prescription which may not be renewed (A)
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 12/04/19
(Click to Download)Click on this link to Download PDF directly
Janssen Sciences Ireland
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 12 April 2019 PIL
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 12 April 2019 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 6 March 2019 PIL
Reasons for updating
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 6 - date of revision
Updated on 6 March 2019 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
CCDS Dec 2016 (092) safety change
Updated on 17 July 2018 PIL
Reasons for updating
- Change to section 6 - what the product contains
- Change to section 6 - date of revision
Updated on 17 July 2018 SmPC
Reasons for updating
- Change to section 6.1 - List of excipients
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
6.1 List of excipients
Butylhydroxytoluene (E321)
Cellulose acetate
Hypromellose (E464)
Phosphoric acid concentrated
Poloxamer 188
Polyethylene oxides 200K and 7000K
Povidone K29-32
Sodium chloride
Stearic acid
Succinic acid
Iron oxide black (E172)
Iron oxide yellow (E172)
Film Coat
Hypromellose (E464)
Lactose monohydrate
Titanium dioxide (E171)
Triacetin
Clear Coat
Carnauba wax
Hypromellose (E464)
Macrogol 400
Printing Ink
Iron oxide black (E172)
Hypromellose (E464)
Isopropyl alcohol
Propylene glycol
Purified water
Updated on 19 February 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 19 February 2018 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Product subject to medical prescription which may not be renewed (A)
Updated on 19 February 2018 PIL
Reasons for updating
- New PIL for new product
Updated on 19 February 2018 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
4.4 Special warnings and precautions for use
Aggressive or hostile behaviour
The emergence or worsening of aggression or hostility can be caused by treatment with stimulants. Aggression has been reported in patients treated with methylphenidate (see section 4.8). Patients treated with methylphenidate should be closely monitored for the emergence or worsening of aggressive behaviour or hostility at treatment initiation, at every dose adjustment and then at least every 6 months and every visit. Physicians should evaluate the need for adjustment of the treatment regimen in patients experiencing behaviour changes bearing in mind that upwards or downwards titration may be appropriate. Treatment interruption can be considered.
Anxiety, agitation or tension
Anxiety, agitation and tension have been reported in patients treated with methylphenidate (see section 4.8). Methylphenidate is also associated with the worsening of pre-existing anxiety, agitation or tension, and anxiety led to discontinuation of methylphenidate in some patients. Clinical evaluation for anxiety, agitation or tension should precede use of methylphenidate and patients should be regularly monitored for the emergence or worsening of these symptoms during treatment, at every adjustment of dose and then at least every 6 months or every visit.
4.6 Fertility, pregnancy and lactation
Methylphenidate has been found in the breast-milk of a woman treated with methylphenidate. Methylphenidate is excreted in human milk. Based on reports of breast milk sampling from five mothers, methylphenidate concentrations in human milk resulted in infant doses of 0.16% to 0.7% of the maternal weight‑adjusted dosage, and a milk to maternal plasma ratio ranging between 1.1 and 2.7.
5.2 Pharmacokinetic properties
Replacement of (0-inf) with inf throughout
Updated on 19 February 2018 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 2 - interactions with other medicines, food or drink
- Change to section 2 - pregnancy, breast feeding and fertility
- Change to section 4 - possible side effects
- Change to section 4 - how to report a side effect
- Change to section 6 - date of revision
- Correction of spelling/typing errors
Updated on 19 April 2017 SmPC
Reasons for updating
- Correction of spelling/typing errors
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 20 March 2017 SmPC
Reasons for updating
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Inclusion of the following wording on Priapism in Section 4.4:
Priapism
Prolonged and painful erections have been reported in association with methylphenidate products, mainly in association with a change in the methylphenidate treatment regimen. Patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.
Addition of Priapism, Erection increased and Prolonged erection as adverse reaction with 'not known' frequency in Section 4.8.
Updated on 17 March 2017 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - date of revision
Updated on 19 May 2016 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Section 4.8
Addition of
Hepatobiliary disorders –very rare- acute hepatic failure
Other ADR changes =changed system organ class
System Organ Class |
Adverse |
|||||||
|
Frequency |
||||||||
|
Very common |
Common |
Uncommon |
Rare |
Very rare |
Not known |
|
||
|
Psychiatric disorders* |
Insomnia, Nervousness |
|
Psychotic disorders*, Auditory, visual and tactile hallucination*, Anger, Suicidal ideation*, Mood altered, Restlessness†, Tearfulness, Worsening of pre-existing tics of Tourette’s syndrome*, Logorrhoea, Hypervigilance, Sleep disorder |
Mania*†, Disorientation, Libido disorder, Confusional state†|
Suicidal attempt (including completed suicide)* †, Transient depressed mood*, Abnormal thinking, Apathy†, Repetitive behaviours, Over-focussing |
Delusions*†, Thought disturbances*, dependence. Cases of abuse and dependence have been described, more often with immediate release formulations |
|
|
|
Hepatobiliary disorders |
|
Alanine aminotransferase increased# |
Hepatic enzyme |
|
Abnormal liver function, including acute hepatic failure and hepatic coma, Blood alkaline phosphatase increased, Blood bilirubin increased†|
|
|
|
|
Investigations |
|
Changes in blood pressure and heart rate (usually an increase)*, Weight decreased* |
Cardiac murmur* |
|
|
|
|
|
|
* See section 4.4 # Frequency derived from adult clinical trials and not on data from trials in children and adolescents; may also be relevant for children and adolescents. †Frequency derived from clinical trials in children and adolescent and reported at a higher frequency in clinical trials in adult patients. |
|
|||||||
Updated on 17 May 2016 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 22 September 2015 SmPC
Reasons for updating
- Change to section 4.7 - Effects on ability to drive and use machines
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Updated on 20 July 2015 SmPC
Reasons for updating
- New individual SPC (was previously included in combined SPC)
Legal category: Product subject to medical prescription which may not be renewed (A)
Free text change information supplied by the pharmaceutical company
Update to section 4.1, 4.2, 4.3 (admin)
Update to section 4.8 _ ADR reporting statement
Update to section 4.9 (overdose)
Treatment
There is no specific antidote to methylphenidate overdosage.
Treatment consists of appropriate supportive measures.
The patient must be protected against self-injury and against external stimuli that would aggravate overstimulation already present. . If the signs and symptoms are not too severe and the patient is conscious, gastric contents may be evacuated by induction of vomiting or gastric lavage. Before performing gastric lavage, control agitation and seizures if present and protect the airway. Other measures to detoxify the gut include administration of activated charcoal and a cathartic. In the presence of severe intoxication, a carefully titrated dose of a benzodiazepine be given before performing gastric lavage The efficacy of activated charcoal has not been established.
Updated on 17 July 2015 PIL
Reasons for updating
- Change to date of revision
- Addition of information on reporting a side effect.
Updated on 2 September 2014 PIL
Reasons for updating
- Change to information about driving or using machinery
- Change to date of revision
Updated on 28 November 2012 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 16 August 2011 PIL
Reasons for updating
- Correction of spelling/typing errors
Updated on 24 June 2011 PIL
Reasons for updating
- Change to, or new use for medicine
- Change to side-effects
- Change to date of revision
Updated on 1 November 2010 PIL
Reasons for updating
- Change to side-effects
Updated on 8 February 2010 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
- Change to side-effects
- Change to drug interactions
- Change to date of revision
- Change due to user-testing of patient information
Updated on 12 February 2009 PIL
Reasons for updating
- PIL re-instated
Updated on 28 August 2008 PIL
Reasons for updating
- Addition of marketing authorisation holder
Updated on 17 October 2007 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change to side-effects
- Change to date of revision
Updated on 3 September 2007 PIL
Reasons for updating
- Change due to harmonisation of patient information leaflet
- Change due to user-testing of patient information
Updated on 16 January 2007 PIL
Reasons for updating
- Change to warnings or special precautions for use
- Change of contraindications
Updated on 19 May 2005 PIL
Reasons for updating
- Change to storage instructions
- Change to warnings or special precautions for use
Updated on 16 November 2004 PIL
Reasons for updating
- New PIL for medicines.ie